Applied Pharmaceutical Analysis 2024
In-Person Event
October 7-9, 2024
Bristol Myers Squibb, Cambridge, MA
Regulated Bioanalysis Workshop - Monday, October 7, 2024
Discovery Bioanalysis and New Technologies Workshop - Tuesday, October 8, 2024
Mechanistic ADME Workshop - Wednesday, October 9, 2024
APA 2024 Program
PLENARY LECTURE William Hwang, MD, PhD Assistant Professor @ Harvard Medical School Understanding the tumor microenvironment using multi-omics and spatial omics - Title TBA |
PLENARY LECTURE Joe Rajarao, PhD, MBA Senior Manager @ Accenture Application of AI in Drug Development |
||
PLENARY LECTURE Terry Van Vleet, PhD, DABT, FATS, ERT Head of Investigative Toxicology and Pathology @ AbbVie Prospects for New Approach Methodologies and Complex In Vitro Models to Reduce, Refine and Replace Animals in Drug Safety Testing |
Ruben Ayala, PhD Lead Pharmacologist, Office of Study Integrity & Surveillance, FDA Recent Data Integrity Findings in Bioresearch Monitoring |
||
Audrey Arjomandi, PhD Principal Scientist @ Genentech Development of Nonclinical Total Anti-drug Antibody (ADA) Assays to Support Zinpentraxin Alfa Reproductive Toxicology Studies |
Jason DelCarpini, PhD Director, Bioanalytical and Molecular Assays @ Moderna bioanalytical considerations for mRNA based therapeutics - Title TBA |
||
Reilly Eason, PhD Senior Scientist @ Merck Basics of Machine Learning and its Applications in Drug Discovery |
Yohei Kosugi, PhD Associate Director @ Takeda Bio-digital transformation of proteomic analysis |
||
Qiushi Liu, PhD Scientist @ Takeda Subcellular Pharmacokinetics/Pharmacodynamics Analysis Using Spatial Transcriptomics Technology - Title TBA |
Lori Payne, PhD Executive Director of Business Development @ Alturas Analytics "Space - the final microsampling frontier/ Mitra Device /Part II" |
||
Jasleen Sodhi, PhD Associate Director @ Septerna Recent developments in predicting CYP-independent metabolism - Title TBA |
Sandhya Subash, PhD Pharmaceutical Chemistry, Research Associate @ Washington State University Uncertainties and Opportunities in Predicting Non-CYP Mediated Drug Metabolism |
||
Xiaomin Wang, PhD Director @ BMS Accelerator Mass Spectrometry (AMS) Applications for Supporting Clinical Development |
Danice Wilkins, PhD Senior Director, Laboratory Sciences @ Charles River Laboratories CRO outcomes shared on regulatory audits - Title TBA |
||
Xiaoyun Yang, PhD Principal Scientist @ Genentech Implementation of Low Volume Sampling Technologies for PK and Biomarker Analysis: Technical and Logistical Challenges and Solutions |
Long Yaun, PhD Director/Head of Bioanalytical Group @ Biogen A Novel Hybridization LC-MS/MS Methodology for Bioanalysis of siRNA |
||
Elaine Tseng, PhD Principal Scientist @ Pfizer Prediction of Drug-Drug Interactions Involving Time-dependent P450 Inhibitors - Title TBA |
Prakash Bolleddula, PhD Clinical Pharmacology Expert - Team Lead @ EMD Serono Translation of Metabolic Clearance for Aldehyde Oxidase Substrates - title TBA |
APA 2024 Sessions
Regulated Bioanalysis Workshop
Session I: Regulatory Audits (M10) and an Industry Perspective on Audits
Session II: Advances in Sampling Strategies and Drug Delivery Innovations
Session III: Advances in Drug Modalities and Emerging Technologies for Characterization
Discovery Bioanalysis and New Technologies Workshop
Session I: Emerging Analytical and Bioanalytical Platform Technology
Session II: Novel Strategies to Advance Biotherapeutic Development
Session III: Recent Case Studies to Support New Modalities
Mechanistic ADME Workshop
Session I: Exploring Therapeutic Paths: PROTACs, ADCs, Macrocyclic Peptides, and DMPK Strategies for Regulatory Success in Gene Therapy, Cell Therapy, and New Modalities
Session II: Unraveling Metabolite Mysteries: Bioactivation, Active Yet Missing Metabolites, and the Enigma of Radiolabel Loss in Mass Balance Studies
Session III: Navigating Complexity: Hepatocyte In Vitro Models for ADME, Unveiling Beyond Rule of Five with In Silico ADME, and Novel In Vitro Approaches in Drug Discovery and Development
Session IV: New Approaches to in Vitro ADME Assays for Improved Drug-Drug-Interaction and Clearance Predictions